Obstructive sleep apnoea treatment and fasting lipids: a comparative effectiveness study

Area of Science:

• Cardiology
• Sleep Medicine
• Metabolic Disorders

Background:

• Obstructive sleep apnoea (OSA) is a known risk factor for cardiovascular disease.
• Dyslipidaemia is hypothesized as a link between OSA and atherosclerosis, but evidence is inconsistent.
• The impact of OSA and its treatment on lipid profiles requires further investigation.

Purpose of the Study:

• To examine the relationship between fasting lipid levels, obesity, and OSA severity.
• To evaluate the effect of positive airway pressure (PAP) treatment on lipid profiles over two years.
• To determine if lipid changes mediate the increased cardiovascular risk associated with OSA.

Main Methods:

• Analysis of fasting lipid levels in 613 moderate-to-severe OSA patients from the Icelandic Sleep Apnoea Cohort.
• Baseline assessment of lipids, obesity, and OSA severity (apnoea/hypopnoea index).
• Two-year follow-up of PAP-treated patients (n=199 adherent, n=118 non-users) using propensity score matching for causal inference.

Main Results:

• Obesity correlated positively with triglycerides and negatively with total cholesterol, LDL, and HDL at baseline.
• A weak association was found between the apnoea/hypopnoea index and HDL cholesterol.
• No significant changes in fasting lipid levels were observed after two years of PAP treatment adherence.

Conclusions:

• Fasting lipid levels do not appear to be a primary mechanism linking OSA to atherosclerotic cardiovascular disease.
• Positive airway pressure treatment does not significantly alter fasting lipid profiles in OSA patients over two years.
• Further research is needed to elucidate the complex relationship between OSA, lipids, and cardiovascular risk.